Alexion Pharmaceuticals Inc., of Boston, appointed Tanisha Carino executive vice president and chief corporate affairs officer, effective Nov. 4.

Aligos Therapeutics Inc., of San Francisco, appointed Matthew W. McClure executive vice president and chief medical officer.

Angion Biomedica Corp., of Uniondale, N.Y., appointed Kevin Norrett senior vice president and chief commercial officer, Tracy Mayne vice president of medical affairs, Daniel Iazzetti vice president of human resources and David Upchurch vice president of technical operations.

Anixa Biosciences Inc., of San Jose, Calif., appointed Thomas Schlumpberger executive vice president, diagnostics and Ian H. Frazer to its scientific advisory board.

Aridis Pharmaceuticals Inc., of San Jose, Calif., appointed Paul Mendelman interim chief medical officer.

Armata Pharmaceuticals Inc., of Marina Del Rey, Calif., appointed Heather Dale Jones medical director and Todd C. Peterson to its board.

Athera Biotechnologies AB, of Stockholm, appointed James Hall CEO.

Azurrx Biopharma Inc., of New York, appointed James Sapirstein president and CEO.

Beam Therapeutics Inc., of Cambridge, Mass., appointed Graham Cooper to its board.

Biomx Ltd., of Ness Ziona, Israel, appointed Merav Bassan chief development officer.

Biospecifics Technologies Corp., of Lynbrook, N.Y., appointed Kevin Buchi CEO and to its board.

Caris Life Sciences Inc., of Irving, Texas, appointed Amalio Telenti, Brian Rubin, Holden Terry Maecker and Hamilton Moses to its scientific advisory board.

Casma Therapeutics Inc., of Cambridge, Mass., appointed Steven Gygi to its scientific advisory board.

Cue Biopharma Inc., of Cambridge, Mass., appointed Aaron Fletcher to its board.

Cytomx Therapeutics Inc., of South San Francisco, appointed Amy C. Peterson executive vice president and chief development officer, Glenn Michelson vice president, clinical development and Jason Braun vice president, commercial strategy.

Deciphera Pharmaceuticals Inc., of Waltham, Mass., appointed Matthew L. Sherman executive vice president and chief medical officer.

Enzyvant Sciences Ltd., of Cambridge, Mass., appointed Jeb Ledell chief operating officer.

FSD Pharma Inc., of Toronto, appointed Stephen Buyer to its board.

Galera Therapeutics Inc., of Malvern, Pa., appointed Christopher Degnan chief financial officer, effective Oct. 21.

Helix Biopharma Corp., of Richmond Hill, Ontario, appointed Ireneusz Fąfara to its board.

Immunic Inc., of San Diego, appointed Tamar Howson to its board.

Kedalion Therapeutics Inc., of Menlo Park, Calif., appointed Mark Blumenkranz CEO, Casey Dougan chief commercial officer and vice president of operations, Reynaldo Quintana senior vice president of research and development and Marc Gleeson to its board.

Lyra Therapeutics Inc., of Watertown, Mass., appointed Dana Washburn chief medical officer.

Magenta Therapeutics Inc., of Cambridge, Mass., appointed Jan Pinkas senior vice president, translational sciences.

Neubase Therapeutics Inc., of Pittsburgh, appointed Steven Dowdy to its scientific advisory board.

Numab Therapeutics AG, of Wädenswil, Switzerland, appointed Daniel Vasella to its board.

Palladio Biosciences Inc., of Newtown, Pa., appointed Marella Thorell chief financial officer.

Poseida Therapeutics Inc., of San Diego, appointed Kerry Ingalls chief operating officer.

Pyxis Oncology Inc., of Boston, appointed Ronald Herbst chief scientific officer.

Seelos Therapeutics Inc., of New York, appointed Scott Applebaum lead strategic regulatory consultant.

Skyhawk Therapeutics Inc., of Waltham, Mass., appointed Ben Blencowe, Ben Ebert, Jeannie T. Lee and Maurice Swanson to its scientific advisory board.

Stemonix Inc., of Maple Grove, Minn., appointed Andrew D. C. LaFrence chief financial officer.

Stoke Therapeutics Inc., of Bedford, Mass., appointed Robin A. Walker senior vice president and chief legal officer and Joan Wood head of human resources.

Vaccibody AS, of Oslo, Norway, appointed Siri Torhaug chief medical officer.

Volitionrx Ltd., of Austin, Texas, appointed Phillip Barnes to its board and audit, compensation and nominations and governance committees.

No Comments